BioCryst Pharmaceuticals Inc (BCRX) — Cash Flow-to-Debt Ratio
BioCryst Pharmaceuticals Inc (BCRX) has a Cash Flow-to-Debt Ratio of -0.06x as of March 2026, meaning its operating cash flow of $-62.14 Million could theoretically repay 0% of its total liabilities ($1.02 Billion) in one year. See BioCryst Pharmaceuticals Inc (BCRX) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BioCryst Pharmaceuticals Inc Cash Flow-to-Debt Ratio (1994–2025)
Historical debt coverage capacity for BioCryst Pharmaceuticals Inc across 32 annual periods. Also explore BCRX net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for BioCryst Pharmaceuticals Inc (1994–2025)
Year-by-year debt coverage analysis for BioCryst Pharmaceuticals Inc. For market capitalisation and broader financial context, see BioCryst Pharmaceuticals Inc stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.52x | $329.88 Million | $633.31 Million | ▲ +1067.6% |
| 2024 | -0.05x | $-52.02 Million | $966.35 Million | ▲ +45.0% |
| 2023 | -0.10x | $-95.14 Million | $972.49 Million | ▲ +48.9% |
| 2022 | -0.19x | $-161.85 Million | $844.60 Million | ▲ +6.3% |
| 2021 | -0.20x | $-142.16 Million | $695.14 Million | ▲ +47.2% |
| 2020 | -0.39x | $-137.22 Million | $353.98 Million | ▲ +40.7% |
| 2019 | -0.65x | $-89.58 Million | $137.03 Million | ▲ +31.1% |
| 2018 | -0.95x | $-92.56 Million | $97.61 Million | ▼ -117.8% |
| 2017 | -0.44x | $-41.14 Million | $94.49 Million | ▲ +28.1% |
| 2016 | -0.61x | $-53.44 Million | $88.27 Million | ▼ -254.6% |
| 2015 | -0.17x | $-13.12 Million | $76.83 Million | ▲ +72.9% |
| 2014 | -0.63x | $-38.55 Million | $61.24 Million | ▼ -18.6% |
| 2013 | -0.53x | $-26.53 Million | $49.99 Million | ▲ +17.8% |
| 2012 | -0.65x | $-37.40 Million | $57.89 Million | ▼ -35.0% |
| 2011 | -0.48x | $-32.25 Million | $67.40 Million | ▲ +26.4% |
| 2010 | -0.65x | $-28.55 Million | $43.94 Million | ▼ -124.1% |
| 2009 | -0.29x | $-16.22 Million | $55.92 Million | ▲ +46.8% |
| 2008 | -0.55x | $-20.87 Million | $38.27 Million | ▼ -69.8% |
| 2007 | -0.32x | $-25.00 Million | $77.81 Million | ▲ +0.0% |
| 2006 | -0.32x | $-15.21 Million | $47.33 Million | ▲ +43.8% |
| 2005 | -0.57x | $-23.35 Million | $40.81 Million | ▲ +90.1% |
| 2004 | -5.79x | $-18.15 Million | $3.13 Million | ▲ +14.7% |
| 2003 | -6.79x | $-11.20 Million | $1.65 Million | ▲ +51.3% |
| 2002 | -13.96x | $-16.36 Million | $1.17 Million | ▼ -213.6% |
| 2001 | -4.45x | $-10.16 Million | $2.28 Million | ▼ -1208.9% |
| 2000 | -0.34x | $-3.18 Million | $9.35 Million | ▲ +86.1% |
| 1999 | -2.45x | $-4.90 Million | $2.00 Million | ▲ +18.3% |
| 1998 | -3.00x | $-4.20 Million | $1.40 Million | ▲ +65.0% |
| 1997 | -8.58x | $-10.30 Million | $1.20 Million | ▼ -114.6% |
| 1996 | -4.00x | $-6.80 Million | $1.70 Million | ▲ +6.5% |
| 1995 | -4.28x | $-7.70 Million | $1.80 Million | ▼ -5.3% |
| 1994 | -4.06x | $-6.50 Million | $1.60 Million | — |